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ABSTRACT 
Objective: The present study deals with the development, validation and application of a simple, precise and accurate HPLC method for the 
determination of mycophenolate mofetil in pharmaceutical formulations and microemulsions. 
Methods: In this method, a simple isocratic mobile phase composition of methanol and water (75:25 v/v) pumped at 1 ml/minute flow rate through 
Phenomenex C18 column (dimension: 250 4.6 mm and 5 µm particle size) was used. Injection volume was 20 µl and analysis of mycophenolate 
mofetil was carried out at 250 nm. 
Results: The coefficient of regression was found to be 0.9996, indicating the linearity of the developed method within a range of 0.1 to 10 µg/ml. 
The limit of detection (LOD) and the limit of quantization (LOQ) were found to be 3.660ng/ml and 11.091ng/ml, respectively. The results showed 
that % deviation for change in compositions of the mobile phase, flow rate and temperature was within a range of-5.51 to 10.99%,-3.70 to 8.80% 
and-5.29 to 10.90%, respectively. The method seemed sensitive to change of temperature (±5 ○C) and methanol composition (±2%) as the results 
were at the boundary limit of 10% deviation. 
Conclusion: A simple, precise and accurate HPLC method for the determination of drug content from microemulsion has been developed and 
validated in accordance with ICH guidelines. 
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INTRODUCTION 
Mycophenolate Mofetil (MMF) is 2-(morpholin-4-yl) ethyl (4E)-6-
(4hydroxy-6-methoxy-7-methyl-3-oxo l, 3 dihydroisobenzofuran-5-
yl)-4-methylhex-4-enoate (fig. 1). It belongs to BCS Class II of drugs 
characterized by a strongly pH-dependent solubility profile [1]. It is an 
immune-suppressant and prodrug of Mycophenolic Acid (MPA), 
extensively used to prevent rejection in organ transplantation [2]. 
MPA, a product of a Penicillium fungus, was originally isolated in 1896. 
The immunological activity of the drug is accomplished through rapid 
hydrolysis (in vivo) of the morpholino-ethyl ester, MMF, to the active 
acid form, MPA [3, 4]. It is a reversible inhibitor of inosine 
monophosphate dehydrogenase (IMPDH) in purine biosynthesis, 
which is necessary for the growth of T cells and B cells. MPA has anti-
neoplastic, anti-viral, anti-fungal and immunosuppressive activity [5]. 
MMF has recently been added to therapeutic regimens for skin 
disorders and it is being actively researched for the treatment of 
psoriasis [6, 7]. There are few reports of dermal formulations in the 
form of the microemulsion, where MMF should be estimated 
accurately during the formulation development stage. Instead of UV 
method, a validated HPLC method for the estimation of MMF is very 
much essential as it gives accurate and precise results. 
 
 
Fig. 1: Structure of mycophenolate mofetil 
According to the guideline Q2 (R1) of ICH, “quantitative tests of the 
active moiety in samples of the drug substance or drug product or 
other selected component(s) in the drug product” is one of the types 
of analytical procedures to be validated [8]. The validation of an 
analytical procedure ensures that the applied analytical technique, 
such as HPLC, shall give reliable and reproducible results. This 
process is very important because it provides information about the 
linearity, accuracy, precision, robustness and sensitivity of the 
method, proving its suitability to the intended application.  
There are few published HPLC methods for the estimation of MMF in 
bulk and plasma samples. Reddy et al. [9] and Rao et al. [10] 
reported such methods for the determination of MMF in tablet 
dosage forms in which mobile phase consisted of acetonitrile and 
phosphate buffer. Tsina et al. [11] reported manual and automated 
HPLC methods for the determination of MMF in human plasma in 
which mobile phase consisted of 0.05M acetonitrile, citrate-
phosphate buffer (pH 3.6) and 0.02M heptane sulfonic acid. All these 
published methods have some significant shortcomings. Their 
mobile phases have buffers as aqueous composition as compared to 
only pure water used for our method. Buffer system creates 
problems as it chokes the analytical column if it is not washed 
thoroughly after the analysis is over. This buffer system is highly 
susceptible to bacterial growth when it is stored. As compared to 
that, our developed HPLC method has a simple mobile phase 
composition of water and methanol only. Moreover, the sensitivity 
of the developed method is quite high as compared to earlier 
published methods. Also, there is no reported HPLC method, which 
was solely developed for the estimation of MMF in micro emulsion 
formulation.  
So, the objective of the present study was to develop and validate a 
simple HPLC method useful for the estimation of MMF in 
microemulsion formulation. Various analytical parameters such as 
linearity, precision, accuracy, robustness, the limit of detection 
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(LOD) and limit of quantification (LOQ) were evaluated as per ICH 
Q2 (R1) guidelines [8]. 
MATERIALS AND METHODS 
Instrumentation 
The separation was carried out on an isocratic HPLC system (Waters 
1525 UV system) attached with binary HPLC pump, Waters 2489 
UV-Visible detector, Empower 3 software and RP-C18 column (250 
mm  4.6 mm; particle size 5 µm). 
Drugs and chemicals 
Mycophenolate Mofetil pure drug was obtained as a gift sample from 
Conchord Biotech, Ahmedabad, India. Labrasol, was obtained as gift 
samples from Gattefosse India Private Limited, Mumbai. Oleic Acid 
and arlasolve were donated by Croda, USA. Methanol of HPLC grade, 
methylparaben and propylparaben were purchased from Loba 
Chemie Pvt. Ltd., India. Ultrapure type I water was obtained from 
Millipure Direct Q, Merck installed at our Department. 
Chromatographic conditions 
The mobile phase consisting of methanol (HPLC grade) and 
ultrapure type I water was sonicated and degassed using a bath 
sonicator before use. It was pumped from the solvent reservoir in 
the ratio of 75:25v/v (methanol: water) into the C18 column at a 
flow rate of 1 ml/min. The column was allowed to equilibrate for 0.5 
h with the mobile before starting the sample run. 20 µl sample was 
injected and the elution was monitored at 250 nm for a time of 10 
min. The whole analysis was performed at 30 ○C. 
Preparation of standard curve (Linearity) 
Standard stock solution of MMF was prepared by dissolving 50 mg 
pure drug in 50 ml standard volumetric flask with methanol 
followed by sonication for 5 min. The obtained solution of 1 mg/ml 
was further diluted to prepare six standard concentrations namely 
0.1, 0.2, 0.5, 2.5, 5 and 10 µg/ml. Each standard concentration was 
run in triplicates and the average value was used for the preparation 
of standard curve by plotting concentration vs peak area. Standard 
curve was constructed with peak area (Y-axis) against concentration 
(X-axis) followed by estimation of coefficient of correlation using 
Microsoft excel. The amount of MMF present in the sample was 
calculated through the standard curve.  
Sensitivity 
Sensitivity of the developed method was determined through 
estimation of limit of detection (LOD) and limit of quantification 
(LOQ). Limit of detection (LOD) is the lowest amount of analyte in 
the sample that can be detected, but not necessarily quantitated as 
an exact value, under the stated conditions of the test. It gives a 
signal-to-noise ratio of about 3:1. Limit of quantification (LOQ) is the 
lowest amount of analyte in the sample that can be quantitatively 
determined with acceptable precision and accuracy under the stated 
conditions of the test. It gives a signal-to-noise ratio of about 10:1. 
The LOD and LOQ of the proposed method were determined from 
the standard curve prepared from standards concentrations in the 
lower ranges (100, 200, 300, 400, 500 and 600 ng/ml) by using 
following equations [12]: 
LOD= 3.3 ------Equation1 
LOQ= 10 -----Equation2 
Where, 
 is standard deviation of intercepts of calibration curve equations. 
S is the mean of slopes of the related calibration curve equations. 
Accuracy and precision 
Accuracy and precision were estimated at three different levels 
corresponding to 80%, 100% and 120% of target concentration i.e. 
3.2, 4.0 and 4.8 µg/ml. six replicates of each sample were prepared 
and analyzed. Precision is expressed as % coefficient of variation 
(%CV), while accuracy is measured as % nominal as per the 
following equations [13].  
Accuracy (% nominal) = 100------Equation3 
Precision (CV %) = 100-----Equation4 
Where, SD is standard deviation. 
Robustness 
Robustness of the proposed method was determined by making 
slight deliberate changes in the experimental procedures. In this 
method, the following changes were applied:  
• Temperature: 5○C 
• Flow rate: 0.1 ml/min 
• Concentration of methanol in the mobile phase: 2%  
Concentration of 4 µg/ml was run with the above conditions and a 
change of<10% in its assay was considered the developed method as 
robust. 
Stability studies 
These include testing of samples that may result in some changes 
during storage and are likely to influence the obtained results. A 
stability study of the proposed method was checked by analyzing the 
sample at 100% of the target concentration (4 µg/ml) by storing the 
sample for 24 h followed by measuring its peak areas after 
appropriate dilution with methanol. The study was repeated in 
triplicate (n=3).  
Application of the developed HPLC Method 
The developed HPLC method was applied to determine the content 
(assay) of MMF from a developed microemulsion formulation. 1% 
MMF microemulsion formulation had the composition of oleic acid, 
labrasol, arlasolve, methylparaben and propylparaben. A volume of 
0.2 ml formulation was taken and diluted with methanol to an 
appropriate concentration. The sample was filtered and analyzed by 
the developed HPLC method. 
RESULTS  
A representative chromatogram of 10 µg/ml MMF sample run at 
previously mentioned chromatographic conditions is given in fig. 2. 
The retention time of MMF was found to be 6.964 min and 
accordingly, a run time of 10 min was fixed for all the analysis. 
Linearity and range 
The calibration curve was prepared within a range of 0.1 µg/ml to 
10 µg/ml by plotting concentration in X-axis and peak area in Y-axis. 
The obtained peak areas of individual calibration standards for three 
replicates are presented in table 1. Overlay chromatograms of the 
standard concentrations is provided in fig. 3. The constructed 
calibration curve over the concentration range of 0.1-10 µg/ml is 
shown in fig. 4. From the regression analysis, the standard curve 
equation was found to be y = 40263x+5350.7 and the coefficient of 
correlation value 0.9996. The LOD and LOQ were found to be 3.66 
ng/ml and 11.09 ng/ml, respectively, which indicates that the 
developed method was quite sensitive. 
Accuracy and precision 
Accuracy and precision were determined by 3 different levels i.e. 80, 
100 and 120% of target concentration at 250 nm using Waters 1489 
UV-visible detector. Nominal % results represent accuracy data, while 
% CV results are used for precision. Accuracy of the developed HPLC 
method ranged from 90.26% to 100.82%, whereas precision results 
were within a range of 0.73 to 2.98 %. The results of accuracy and 
precision for the developed HPLC method are given in table 2. 
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Fig. 2: A typical RP-HPLC chromatogram of mycophenolate mofetil (10 µg/ml) showing retention time 6.964 min 
 
Table 1: Linearity of MMF using RP-HPLC technique 
Concentration (µg/ml) Area1 (µV*sec.) Area2 (µV*sec.) Area 3 (µV*sec.) aMean Area±SD (µV*sec.) 
0.1 6915 9124 8556 8198.33±1147.11 
0.2 13202 15779 13698 14226.33±1367.33 
0.5 31085 30896 28507 30162.67±1436.96 
2.5 110397 110071 99154 106540.67±6399.12 
5 217847 211238 196094 208393.00±11152.07 
10 385260 416054 418909 406741.00±18657.78 
amean±SD for 3 determinations 
 
 
Fig. 3: Overlay chromatogram of the standard concentrations 
 
 
Fig. 4: Standard curve of mycophenolate mofetil at 250 nm 
Mandal et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 4, 16-20 
19 
Table 2: Results of accuracy and precision for the HPLC method 
True conc. 
(µg/ml) 
Observed conc. (µg/ml) aMean conc. 
(µg/ml) 




3.2 3.165 3.166 3.129 3.115 3.109 3.095 3.130 0.030 97.81 0.95 
4.0 3.755 3.687 3.672 3.501 3.531 3.516 3.610 0.107 90.26 2.98 
4.8 4.857 4.852 4.884 4.785 4.847 4.812 4.840 0.036 100.82 0.73 
aMean for 6 determinations 
 
Robustness 
Robustness of the developed analytical method was tested by 
evaluating the influence of minor modifications in HPLC conditions 
on system suitability parameters of the proposed method. The 
results of robustness testing are summarized in table 3, 4 and 5. 
Stability studies 
MMF sample of 4 µg/ml (correspond to 100% of target 
concentration) was stored for 24 h at room temperature and then 
analyzed and % degradation of the sample was determined. The 
results of the same are provided in table 6. 
  
Table 3: Results of robustness with respect to change in composition of mobile phase 
Water: methanol (v/v) Run 1 (µg/ml) Run 2 (µg/ml) Run 3 (µg/ml) aMean conc.±SD (µg/ml) % Deviation 
24:76 3.414 3.535 3.554 3.501±0.076 -5.51 
25:75 3.755 3.687 3.672 3.705±0.044 (100%) ---- 
26:74 4.109 4.13 4.096 4.112±0.017 +10.99 
amean±SD for 3 determinations 
 
Table 4: Results of robustness for change in flow rate 
Flow rate (ml/min) Run 1 (µg/ml) Run 2 (µg/ml) Run 3 (µg/ml) aMean conc.±SD (µg/ml) % Deviation 
0.9 3.825 3.859 3.842 3.842±0.017 -3.70 
1 3.755 3.687 3.672 3.705±0.044 (100%) ---- 
1.1 3.397 3.359 3.381 3.379±0.019 +8.80 
amean±SD for 3 determinations 
 
Table 5: Results of robustness for change in temperature 
Temperature (○C) Run 1 (µg/ml) Run 2 (µg/ml) Run 3 (µg/ml) aMean conc.±SD (µg/ml) % Deviation 
25 4.135 4.134 4.057 4.109±0.045 +10.90 
30 3.755 3.687 3.672 3.705±0.044 (100%) ---- 
35 3.516 3.515 3.495 3.509±0.012 -5.29 
amean±SD for 3 determinations 
 
Table 6: Results of stability study 
Initial conc.(µg/ml) Run 1 (µg/ml) Run 2 (µg/ml) Run 3 (µg/ml) aMean conc.±SD (µg/ml) %Degradation 
3.705 3.694 3.596 3.436 3.575±0.130 3.51 
amean±SD for 3 determinations 
  
 
Fig. 5: Representative chromatogram of a test sample used for determination of drug content (Mycophenolate Mofetil) in a microemulsion 
formulation 
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DISCUSSION 
Analytical procedure explains the method by which analysis can 
be performed and describes the steps necessary for the analytical 
test. Validation of an analytical method establishes documented 
evidence and provides a high degree of assurance that the method 
will consistently produce the desired result meeting its 
predetermined specifications and quality characteristics [14]. The 
UV absorption spectrum of the representative sample (10µg/ml) 
of MMF was scanned and showed three major peaks at 215 nm, 
250 nm, and 304 nm. In spite of maximum absorbance as 
compared to the other two peaks, 215 nm was not selected for our 
study, assuming it might have interaction with micro emulsion 
compositions. Between 250 nm and 304 nm, 250 nm was chosen 
as λmax due to its higher absorbance value. The constructed 
calibration curve resulted in a coefficient of correlation value 
0.9996, which indicates a linear relationship between the 
concentrations of analyte and areas of the corresponding peaks. 
The results of accuracy and precision were found to be within the 
limits of ICH Q2 (R1) guidelines [15]. 
The results of robustness studies showed that a minor change of 
method conditions such as the compositions of the mobile phase, 
flow rate and temperature, is robust within the acceptable limits. 
The % deviation between actual and observed concentration was 
calculated. The results show that % deviation for change in 
compositions of the mobile phase, flow rate and temperature was 
within a range of-5.51 to 10.99%,-3.70 to 8.80% and-5.29 to 10.90%, 
respectively. The method seems sensitive to change in temperature 
(±5 ○C) and methanol composition (±2%) as the results were at the 
boundary limit of 10% deviation. However, the changes below±5 ○C 
and±2% methanol should not affect the method. 
The sample was found quite stable; maximum degradation was 
found at 3.51%. The results (table 6) show that the developed HPLC 
method for estimation of MMF is quite stable up to 24 h. The 
developed HPLC method was successfully applied to estimate the 
content of MMF present in the developed micro emulsion 
formulation.  
CONCLUSION 
An HPLC method for the estimation of MMF was developed and 
validated as per ICH Q2 (R1) guidelines. A simple mobile phase 
consisting of only water and methanol at 75 and 25 ratios (v/v) 
was used. The developed method was very much sensitive, with 
LOD and LOQ values of 3.660 ng/ml and 11.091 ng/ml, 
respectively. The method was linear in the range of 0.1 to 10 
µg/ml. Accuracy, precision, stability and robustness parameters 
were within limits. The developed method was successfully 
utilized to estimate drug content of a developed micro emulsion 
formulation. 
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